Jasper Therapeutics, Inc.
JSPR · XNASCIK 1788028fmd_0EQ28RZEHGGJ3CQHNBYKAZF6XAManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Jun 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Net interest income | (0) | (0) | (0) | (0) | – | – |
| Cost of revenue | – | – | – | – | 34 | 42 |
| Research and development | 16 | 25 | 35 | 52 | 56 | 63 |
| Total operating expenses | 21 | 37 | 51 | 69 | 76 | 84 |
| Operating income | (21) | (37) | (51) | (69) | (76) | (84) |
| Interest and investment income | – | – | 1 | 5 | 5 | 2 |
| Other non-operating income (expense) | – | (0) | 1 | 4 | 5 | 8 |
| Income before taxes | (6) | – | – | – | – | – |
| Income tax expense | 0 | – | – | 0 | 0 | – |
| Net income from continuing operations | (6) | – | – | – | – | – |
| Net income | (32) | (31) | (38) | (64) | (71) | (76) |
| Net income to common shareholders | (32) | (31) | (38) | (64) | (71) | – |